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Background: Experimental studies in rodents suggest that polybrominated diphenyl ethers (PBDEs) and polyand perﬂuoroalkyl substances (PFAS) may contribute to depressive symptoms. Few studies have examined the
impact of these chemicals on depression in adults.
Objective:
To examine the associations between serum PBDE and PFAS concentrations during pregnancy and repeated
measures of depressive symptoms in women assessed from pregnancy to 8 years postpartum.
Methods:
This study was based on 377 women from the Health Outcomes and Measures of the Environment Study, a
birth cohort in Cincinnati, OH (USA). PBDEs (BDE-28, -47, -99, -100, -153, and ∑PBDEs) and PFAS (perﬂuorooctanoate [PFOA], perﬂuorooctane sulfonate [PFOS], perﬂuorohexane sulfonate [PFHxS], perﬂuorononanoate [PFNA]) were quantiﬁed in maternal serum at 16 ± 3 weeks gestation. Depressive symptoms
were measured using the Beck Depression Inventory-II (BDI-II) at ~20 weeks gestation and up to seven times
during postpartum visits (4 weeks, 1, 2, 3, 4, 5, and 8 years). We used linear mixed models to estimate covariateadjusted associations between chemical concentrations and repeated measures of BDI-II. Multinomial logistic
regression models were used to estimate the relative risk ratios of having a medium or high depression trajectory.
Results:
We found that a 10-fold increase in BDE-28 at 16 ± 3 weeks gestation was associated with signiﬁcantly
increased BDI-II scores (β = 2.5 points, 95% conﬁdence interval [CI] 0.8, 4.2) from pregnancy to 8 years
postpartum. Signiﬁcant positive associations were also observed with BDE-47, -100, -153, and ∑PBDEs. A 10-fold
increase in ∑PBDEs was associated with a 4.6-fold increased risk (95% CI 1.8, 11.8) of a high trajectory for BDI-II
compared to a low trajectory. We observed no signiﬁcant associations between PFAS and BDI-II scores.
Conclusion:
PBDEs during pregnancy were associated with more depressive symptoms among women in this cohort.
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1. Introduction

2016; Patel et al., 2016; Salgado et al., 2016). Both PBDEs and PFAS
have been identiﬁed to disrupt thyroid hormones in humans
(Ballesteros et al., 2017; Czerska et al., 2013; Herbstman and Mall,
2014; Kim et al., 2018). PBDEs may disrupt thyroid hormone homeostasis via competitive binding to thyroid hormone receptors and
thyroid transport protein transthyretin as well as inducing thyroxine
glucuronidation, thereby increasing thyroxine clearance (Meerts et al.,
2000; Richardson et al., 2008; Zhou et al., 2002). Reductions in thyroxine observed with PFAS exposure may be due to increased metabolism from upregulating hepatic transport proteins, increased glucuronidation, upregulated deiodinase enzyme DIO1, and displaced
thyroxine-bound receptors (Chang et al., 2008; Weiss et al., 2009; Yu
et al., 2009; Yu et al., 2011). Hypothyroidism and subclinical hypothyroidism have been associated with depressive symptoms (Hage
and Azar, 2012; Loh et al., 2019).
No study has examined PBDEs or PFAS during pregnancy and maternal depression. Given the potential for PBDEs and PFAS to contribute
to the pathophysiology of depression based on mechanisms demonstrated by PCBs as well as the relatively long half-lives of these compounds in the human body, we investigated the relationship between
serum concentrations of PBDEs and PFAS among women in their early
second trimester of pregnancy and depressive symptoms from pregnancy to 8 years postpartum. In addition to analysis of outcome at an
individual time point, we examined the trajectories of depressive
symptoms to reﬂect patterns of symptom change during this period. We
hypothesize that PBDE and PFAS concentrations during pregnancy are
associated with more depressive symptoms in women as well as a trajectory of depression throughout the period.

The prevalence of clinically signiﬁcant depression in women, deﬁned as severe symptoms aﬀecting various aspects of daily life that
persists for at least two weeks, ranges from 10 to 23% during pregnancy
and postpartum (Bennett et al., 2004; Ertel et al., 2011; Mayberry et al.,
2007). Women who experience symptoms of depression during this
time may face many issues, including more sexual problems, deﬁcient
social support systems, increased risk of anemia, increased anxiety and
fatigue, loss of sleep, and more harmful health behaviors, including
alcohol and substance abuse (Asselmann et al., 2016a, 2016b; Kang
et al., 2020; Zuckerman et al., 1989). Maternal depression is also associated with lower maternal functioning. Studies report that mothers
with depression are less sensitive to child cues, provide less positive
stimulation, have more parenting diﬃculties, and are less adherent to
medical and preventive practices than their non-depressed counterparts
(Coyl et al., 2002; Field, 2002; Leiferman, 2002; McLennan and
Kotelchuck, 2000; Pelaez et al., 2008). Maternal depression has been
documented to adversely aﬀect oﬀspring health, from infancy to adolescence (Campbell et al., 2009; Field et al., 2006; Goodman et al.,
2011; Stewart, 2007). Children of depressed mothers are more likely to
experience general psychopathology, exhibit more internalizing and
externalizing problems, suﬀer from diminished cognitive functioning,
and display suboptimal physical growth (Ertel et al., 2010; Goodman
et al., 2011; Hay et al., 2008). Maternal depression during childhood is
also associated with poorer academic performance (Murray et al.,
2010). Adverse cognitive and behavioral outcomes in children may
persist even after remission of maternal depression (Moehler et al.,
2006; Murray, 1992; Murray et al., 1996), although some studies suggest psychotherapy and antidepressant treatment can improve outcomes for both women and their children (Goodman and Garber, 2017).
Studies have found that alleviating maternal depression can improve
children’s mental health as well as reducing internalizing and externalizing behavioral problems (Cuijpers et al., 2015; Forman et al.,
2007).
Depression is aﬀected by alterations in the hypothalamic-pituitarythyroid axis (Loh et al., 2019). In addition, dopamine dysfunction,
particularly diminished dopaminergic neurotransmission, is involved in
the pathophysiology of depression (Dunlop and Nemeroﬀ, 2007). Reductions in dopamine release and impairments in signal transduction
are potential underlying mechanisms contributing to depressive
symptoms. Polybrominated diphenyl ethers (PBDEs) and poly- and
perﬂuoroalkyl substances (PFAS) are endocrine disrupting chemicals
that may play a role in the pathomechanism of depression by disrupting
dopamine and thyroid function - similar to that observed for exposure
to polychlorinated biphenyls (PCBs), which are structurally similar to
PBDEs and share physiochemical properties (Gaum et al., 2019).
PBDEs are ﬂame retardants that were used in polyurethane foam for
furniture and carpet padding and in the hard plastic casings in appliances and electronics. Despite the phase out of Penta- and OctaBDE in
2004 and DecaBDE subsequently in 2013 (Linares et al., 2015), BDE-28,
-47, -99, -100, and -153 were still detected in > 90% of the general U.S.
population in the National Health and Nutrition Examination Survey
(NHANES) for the years 2005/2006 through 2013/2014 (Sjodin et al.,
2019). Interest in PBDEs as potential chemicals of concern for depression stem from their similar structure and toxicological properties to
PCBs, which have been documented to interfere with the dopamine
system by disrupting tyrosine hydroxylase activity, disturbing dopamine transport, and aﬀecting dopamine metabolism (Choksi et al.,
1997; Fonnum and Mariussen, 2009; Putschogl et al., 2015; Seegal
et al., 2010). PBDEs have also been reported to disrupt the dopaminergic system (Bradner et al., 2013; Slotkin et al., 2013; Wang et al.,
2015). PFAS may play a role in the etiology of neuropsychiatric disorders by altering dopaminergic synapses, disturbing dopaminergic
gene transcription, modifying neuronal activity, and inhibiting gene
and protein expression of dopamine receptors (Hallgren and Viberg,

2. Methods
2.1. Study design and cohort
The Health Outcomes and Measures of the Environment (HOME)
Study is an ongoing prospective pregnancy and birth cohort of motherchild dyads in the greater Cincinnati area (Braun et al., 2017a). Pregnant women were recruited from March 2003 to February 2006 from
nine prenatal clinics if they met the following inclusion criteria: (1)
18 years of age; (2) 16 ± 3 weeks of gestation; (3) residing in housing
constructed before 1978; (4) receiving and planning to continue prenatal care and deliver at one of the collaborating obstetric practices; (5)
HIV- status; and (6) not taking any medications related to seizures,
thyroid disorders, or chemotherapy/radiation. Of the 1263 eligible
women identiﬁed via clinical records and phone interviews, there were
468 women who enrolled and 390 who subsequently delivered liveborn
singletons. Follow-up visits consisted of home visits, telephone interviews, and clinic visits. Participants missing a particular follow-up visit
(e.g., 2 year postpartum) were not excluded from the study and might
complete a subsequent follow-up visit (e.g., 5 years postpartum). The
availability of at least one assessment of depressive symptoms was a
requirement to be included in the present study, as a longitudinal mixed
model was employed. A total of 377 had at least one assessment of
depressive symptoms from baseline to 8 years postpartum and a measurement of either PBDEs or PFAS quantiﬁed at enrollment. Of these
women, biomonitoring was completed during pregnancy for the following: 96% (n = 361) for PBDEs, 94% (n = 360) for PFAS, and 90%
(n = 339) for both chemical classes. The study protocol was approved
by the Institutional Review Board (IRB) at the Cincinnati Children’s
Hospital Medical Center (CCHMC). The Centers for Disease Control and
Prevention (CDC) deferred to CCHMC IRB as the IRB of record.
2.2. Concentrations of PBDEs and PFAS
Maternal blood samples were collected at ~16 ± 3 weeks gestation. Serum was separated and stored at −70 °C until analysis. Details
regarding quality assurance, quantiﬁcation procedures, and lipid
2
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visit-speciﬁc estimates because the interaction terms between continuous measures of our exposure (PBDEs or PFAS) and visit (categorical) were not all statistically signiﬁcant (see Supplemental Tables S3
and S4). We also examined whether higher concentrations of PBDEs or
PFAS were associated with higher odds of having a score “at risk” of
depression, deﬁned in our study as a BDI-II score > 13, using generalized linear models.
We categorized women into three diﬀerent groups according to
their 9-year longitudinal trajectory of BDI-II score patterns from early
second trimester of pregnancy to 8 years postpartum. The group-based
trajectory modeling (GBTM) was performed using Stata/IC 12.1 procedure Traj to identify clusters of individuals with similar progressions
of BDI-II scores using a zero-inﬂated Poisson model with a quadratic
polynomial trajectory function that allows for an inﬂection point within
the data (Jones and Nagin, 2013; Nagin et al., 2018). GBTM assumes
that the population distribution of BDI-II trajectories arises from a ﬁnite
mixture of unknown groups. It does not identify a true number of trajectory groups since there is no true number, but it distinguishes distinct features of the population with similar trajectories. Using a general
quasi-Newton procedure, GBTM predicts each groups’ trajectory, estimates the probability that an individual is within each group, and assigns an individual to the group that they have the highest probability
to be in. Almost half of the women in the HOME Study had a BDI-II
score trajectory that was categorized as low, 40% of women were categorized as medium, and about 10% had a high depression trajectory
(Fig. 1). We used multinomial logistic regression models to estimate the
excess relative risk of being in the medium or high BDI-II score trajectory relative to the low trajectory with increasing PBDE or PFAS
concentrations, yielding relative risk ratios (RRRs) and 95% CIs. All
models were adjusted for maternal age, race/ethnicity, household income at enrollment, self-reported marijuana use during pregnancy,
serum cotinine as a measure of tobacco use or secondhand smoke exposure, serum ∑PCBs, maternal IQ, marital status, and parity based on a
review of the literature and bivariate analysis with both exposure and
outcome (p < 0.20).
We conducted a sensitivity analysis using only PFAS concentrations
measured at 16 ± 3 weeks of gestation, regardless of whether the
participant had more than one measurement at multiple time points
(n = 303) to address potential concerns of exposure misclassiﬁcation
bias. We also performed a number of sensitivity analyses with additional adjustment for pre-pregnancy body mass index (BMI), blood lead
levels during pregnancy, if women breastfed (yes/no), alcohol consumption (never, < 1/month, > 1/month), and polyunsaturated fatty
acid (PUFA) intake to alleviate concerns of residual confounding outside of the covariates included in our ﬁnal model. PUFA levels were

adjustment have been described previously (Vuong et al., 2016).
Brieﬂy, gas chromatography/isotope dilution high-resolution mass
spectrometry was used to quantify PBDE congeners -17, -28, -47, -66,
-85, -99, -100, -153, -154, and -183 (Jones et al., 2012; Sjodin et al.,
2004). For the present study, we focused on PBDE congeners BDE-28,
-47, -99, -100, and -153, as well as their sum (∑PBDEs), which had
detection frequencies > 87% (see Supplemental Table S1). Because
detection frequencies were high and percentages of PBDE measurements below the limit of detection (LOD) were low, we substituted
values < LOD with LOD/√2 as recommended by Hornung and Reed
(1990).
PFAS compounds, including perﬂuorooctanoate (PFOA), perﬂuorooctane sulfonate (PFOS), perﬂuorohexane sulfonate (PFHxS), and
perﬂuorononanoate (PFNA), were measured using on-line solid-phase
extraction coupled to high-performance liquid chromatography-isotope
dilution-tandem mass spectrometry (Kato et al., 2011). For women
without PFAS measurements at 16 ± 3 weeks, we substituted measurements quantiﬁed at 26 weeks gestation (n = 35) or at parturition
(n = 17). For those with > 1 measurement during pregnancy (n = 70),
an average was used for prenatal PFAS. All PFAS compounds were
detected in all serum samples (see Supplemental Table S1). PBDEs and
PFAS concentrations were log10- and ln-transformed (due to a lower
range of concentrations), respectively, to reduce the inﬂuence of outliers.
2.3. Maternal depression
Maternal depressive symptoms were measured using the Beck
Depression Inventory-II (BDI-II) at ~20 weeks of gestation and seven
postpartum visits, including 4 weeks, 1, 2, 3, 4, 5, and 8 years (Beck
et al., 1996). For the majority of women, the BDI-II was self-administered. In a few cases when literacy was in question, it was administered
orally by a research assistant. All research assistants were trained in
proper administration and scoring of the measure by a developmental
psychologist with over 25 years of experience in test administration,
scoring, and interpretation. The 21-item questionnaire consisted of
areas related to mental and somatic components of depression. Symptoms of depression may include feelings of hopelessness or irritability,
and signs of depression may manifest physically, such as feeling fatigue,
experiencing weight loss, or lacking interest in sex. Responses were
rated on a 4-point Likert scale, from 0, “not at all,” to 3, “severely.”
Total scores on the BDI-II ranged from 0 to 63, with scores ≤13 considered “minimally depressed,” 14–19 considered “mildly depressed,”
20–28 considered “moderately depressed,” and > 28 considered “severely depressed.” Because of the low percentages of HOME Study
women who had BDI-II scores considered moderately, severely, or
clinically depressed, we categorized BDI-II scores into > 13 as women
exhibiting “some depressive symptoms,” and ≤13 as women exhibiting
“little to no depressive symptoms” (see Supplemental Table S2). Research coordinators executing the study visits did not have knowledge
of the participants’ previous responses on the measure. They also did
not have information about speciﬁc exposures of interest at the time of
the study visit. Protocols for explaining the BDI-II, providing instructions for its completion, review and tally of total scores according to the
published manual, and delivery of intervention (as needed) were employed to ensure standardization of the process across all study participants.
2.4. Statistical methods
Intraclass correlation coeﬃcients were calculated for BDI-II scores
measured at 8 visits. We used linear mixed models to estimate βs and
95% conﬁdence intervals (CIs) for individual PBDEs, ∑PBDEs, and the
four individual PFAS in relation to repeated measurements of BDI-II
scores assessed from ~20 weeks of gestation to 8 years postpartum. We
only present overall estimates for repeated BDI-II scores rather than

Fig. 1. Trajectories of BDI-II scores from pregnancy to 8 years postpartum,
HOME Study.
3
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calculated based on reported total intake of ﬁsh consumption (types,
frequency) during pregnancy using data from the USDA National
Nutrient Database. We also adjusted for time varying covariates, including household income, marital status, paternal education, perceived social support, and neighborhood quality, to take into account
changes that may have occurred following baseline which may have
resulted in information bias. Social support was categorized into high,
moderate, and low based on participant responses to questions inquiring about help received from family and friends living nearby. It
was measured by two questions inquiring about family and friends,
which asked, “How much help would you expect to get from [FAMILY/
FRIENDS] living nearby?” Neighborhood quality was determined based
on two sets of questions. First, regarding the likelihood of participants’
neighbors getting involved in various scenarios involving their children, the neighborhood, and the community. The ﬁrst set of questions
for neighborhood involvement contained ﬁve questions asking, “How
likely would your neighbors intervene if…”: (1) “children were skipping school and hanging out on a street corner?”; (2) “if children were
spray-painting graﬃti on a local building?”; (3) “if children were
showing disrespect to an adult?”; (4) “a ﬁght broke out in front of their
house?”; and (5) “the ﬁre station closest to their house was threatened
with budget cuts?” Second, participants were asked to agree with
statements inquiring about the willingness of neighbors to help others,
the level of familiarity within the neighborhood, trustworthiness, and
the ability of neighbors to get along. The set of ﬁve statements consisted
of the following: (1) “People around my home are willing to help their
neighbors”; (2) “I live in a close-knit neighborhood”; (3) “People in my
neighborhood can be trusted”; (4) People in my neighborhood generally
don’t get along with each other”; and (5) “People in my neighborhood
do not share the same values.”

3.3. Serum PBDEs and PFAS during pregnancy and maternal depression
BDI-II scores were positively associated with concentrations of
PBDEs during pregnancy after covariate adjustment (Fig. 2). Aside from
BDE-99, all PBDE congeners and ∑PBDEs were signiﬁcantly positively
associated with BDI-II scores. A 10-fold increase in BDE-28 concentrations at 16 ± 3 weeks gestation was associated with a 2.5-point increase (95% CI 0.8, 4.2) in BDI-II scores from pregnancy to 8 years
postpartum. We observed similar statistically signiﬁcant positive associations between BDI-II and BDE-47, -100, -153, and ∑PBDEs. Higher
odds of having a BDI-II score > 13 from pregnancy to 8 years postpartum was observed among women with higher concentrations of
BDE-28, -47, -100, -153, and ∑PBDEs (see Supplemental Table S5). A
10-fold increase in ∑PBDEs during the early second trimester of pregnancy was signiﬁcantly associated with approximately a 2-fold risk
(95% CI 1.4, 4.2) of having a BDI-II score that would indicate potential
depressive symptoms from pregnancy to 8 years postpartum.
When we examined trajectories of maternal depressive symptoms,
we observed signiﬁcantly higher risk of having a high BDI-II score
trajectory with 10-fold increases in several PBDE congeners and
∑PBDEs compared to a low BDI-II score trajectory (Table 2). Both BDE47 and BDE-99 had statistically signiﬁcant RRRs for medium and high
BDI-II score trajectories. A 10-fold increase in ∑PBDEs was associated
with a 4.6 increase in risk (95% CI 1.8, 11.8) of having a high BDI-II
trajectory compared to a low trajectory.
Serum concentrations of PFAS during pregnancy were not associated with BDI-II scores measured from pregnancy to 8 years postpartum (Fig. 2). In addition, no relationship was noted between PFAS
and higher odds of having an “at risk” BDI-II score (see Supplemental
Table S5).
3.4. Sensitivity analyses

3. Results
Examination of PFAS measured only at 16 weeks gestation did not
yield ﬁndings that were discordant from our original results
(Supplemental Table S6). Additional adjustment for perceived social
support and neighborhood quality, pre-pregnancy BMI, blood lead levels during pregnancy, breastfeeding, alcohol consumption, and PUFA
levels did not change our results (see Supplemental Table S7). After
including paternal education at baseline as well as a time-varying paternal education variable in two separate sensitivity analyses, we no
longer observed a signiﬁcant association between BDE-100 and BDI-II
scores (see Supplemental Table S8). However, all other signiﬁcant positive associations between BDE-28, -47, -153, and ∑PBDEs remained.

3.1. Study participants
The mean age at baseline was 29.4 years, with 61.8% of the women
identifying as non-Hispanic white and 50% having a Bachelor’s degree
or higher. Approximately 60% had an annual household income at
baseline ≥$40,000, and 79% were married or living with a partner.
Concentrations of ∑PBDEs during pregnancy were lower among older
women, non-Hispanic whites, those with higher education and income,
and among women who were married/living with a partner (Table 1).
PFOA and PFOS concentrations were higher among non-Hispanic
whites and among women who were nulliparous. Lower BDI-II scores
during pregnancy and at 8 years postpartum were observed among
women who were non-Hispanic white, married or living with a partner,
more educated, had a higher household income, and non-marijuana
users.

4. Discussion
In the HOME Study, we found that PBDE concentrations during
pregnancy were signiﬁcantly associated with higher depressive symptoms in women. Several PBDE congeners as well as ∑PBDEs had statistically signiﬁcant positive associations with BDI-II scores, suggesting
that PBDEs may play a role in the pathogenesis of depression. In contrast, there was no evidence to indicate that serum concentrations of
PFAS during pregnancy are related to maternal depressive symptoms.
Some studies have examined PBDEs and internalizing behaviors in
children. While most reported null associations (Braun et al., 2017b;
Chen et al., 2014; Gump et al., 2014; Hoﬀman et al., 2012), higher
PBDE concentrations have been associated with improvement in internalizing behaviors in some studies (Adgent et al., 2014; Roze et al.,
2009) and worsening of internalizing behaviors in others (Lipscomb
et al., 2017). Because no studies have examined PBDEs and depression
in adults, studies investigating PCBs and depression in adults may serve
as a comparison as PBDEs are structurally similar and have analogous
toxicological properties (Costa et al., 2014). In a longitudinal study,
individuals with a higher PCB burden had increased risk of developing
depressive symptoms (Gaum et al., 2014). PCBs were also positively

3.2. Longitudinal trends of maternal depression
The intraclass correlation coeﬃcient for BDI-II scores was 0.58,
indicating good reproducibility between BDI-II assessments across time.
BDI-II scores were highest during pregnancy, with a mean of
10.0 ± 7.0 (see Supplemental Table S2). Scores declined after delivery, with the lowest mean of 5.5 ± 6.0 at 5 years postpartum.
However, at 8 years postpartum, the mean of BDI-II scores increased to
7.4 ± 7.3. The percentage of women exhibiting some depressive
symptoms (BDI-II scores > 13) was highest during pregnancy (22.3%)
followed by 8 years postpartum (18.4%). Moderately and severely depressed women, deﬁned as individuals with a BDI-II score ≥20, were
observed in less than 10% of the HOME Study women at every time
point.

4
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Table 1
Serum concentrations of ∑PBDEs (ng/g lipid), PFOA and PFOS (both in ng/mL), and BDI-II scores by maternal characteristics, HOME Study.a
∑PBDEs

PFOA

PFOS

BDI-II: Baseline

BDI-II: 8 years

n

GM ± GSD

n

GM ± GSD

n

GM ± GSD

n

GM ± GSD

n

GM ± GSD

Age, years
< 25
25–34
≥35

74
179
47

47.5 ± 2.2*
39.6 ± 2.7
29.4 ± 2.5

87
210
57

5.5 ± 1.8
5.1 ± 1.7
5.9 ± 1.8

87
210
57

12.2 ± 1.9
12.7 ± 1.6
14.1 ± 1.6

87
226
60

13.7 ± 8.4*
8.8 ± 6.1
8.8 ± 6.4

59
131
32

8.9 ± 7.5
6.8 ± 7.1
7.3 ± 7.5

Race/ethnicity
Non-Hispanic White
Non-Hispanic Black and Others

183
118

32.5 ± 2.5*
53.1 ± 2.6

216
139

5.6 ± 1.7*
4.8 ± 1.7

216
139

13.9 ± 1.6*
11.1 ± 1.8

231
142

7.9 ± 5.6*
13.2 ± 7.9

135
88

6.0 ± 6.6*
9.6 ± 7.7

Education
High school or less
Some college/2 yr degree
Bachelor’s
Graduate or professional

83
72
88
57

56.4
40.5
34.1
28.7

2.4*
2.3
2.5
3.1

94
86
105
69

5.2
5.4
5.5
5.1

1.8
1.7
1.8
1.7

94
86
105
69

11.3
12.9
13.4
13.7

97
88
109
79

14.5 ± 9.1*
11.1 ± 6.3
7.4 ± 4.3
6.7 ± 4.2

61
57
65
39

9.8
9.2
5.2
5.0

Family Income
< $40,000
$40,000–$79,999
≥$80,000

123
97
81

49.3 ± 2.6*
37.8 ± 2.6
29.5 ± 2.4

145
113
97

4.9 ± 1.8
5.5 ± 1.7
5.7 ± 1.8

145
113
97

11.2 ± 1.9*
13.3 ± 1.6
14.7 ± 1.6

147
123
103

13.4 ± 8.5*
8.3 ± 5.0
7.1 ± 4.4

92
73
58

9.7 ± 7.6*
5.4 ± 6.9
6.3 ± 6.1

Marijuana Use
Yes
No

277
23

38.5 ± 2.6
54.5 ± 2.2

329
25

5.3 ± 1.7
5.0 ± 1.8

329
25

13.1 ± 1.7*
9.0 ± 1.9

344
29

9.4 ± 6.6*
16.4 ± 8.7

207
15

7.0 ± 7.0*
13.7 ± 8.6

Parity
Nulliparous
Primiparous
Multiparous

132
90
76

35.2 ± 2.6
41.6 ± 2.4
44.4 ± 2.7

153
110
89

6.5 ± 1.7*
4.4 ± 1.6
4.7 ± 1.7

153
110
89

14.7 ± 1.7*
11.9 ± 1.7
10.9 ± 1.6

166
115
90

9.2 ± 5.8
10.0 ± 8.5
11.3 ± 6.9

103
65
54

6.7 ± 7.2*
6.3 ± 5.7
10.1 ± 8.4

Marital status
Married/living with partner
Not married, living alone

236
64

35.7 ± 2.7*
57.6 ± 2.1

278
76

5.3 ± 1.8
5.3 ± 1.6

278
76

13.0 ± 1.7
11.9 ± 1.8

296
77

8.9 ± 6.5*
13.9 ± 7.8

165
57

6.4 ± 6.8*
10.3 ± 7.9

Child Sex
Male
Female

138
162

34.8 ± 2.5*
44.1 ± 2.7

166
188

5.2 ± 1.7
5.4 ± 1.7

166
188

12.6 ± 1.7
12.9 ± 1.8

172
201

9.0 ± 6.4*
10.8 ± 7.5

99
123

6.8 ± 6.1
8.0 ± 8.0

Breastfed current child
No
Yes

53
236

46.3 ± 2.2
38.0 ± 2.6

66
277

5.5 ± 1.6
5.3 ± 1.8

66
277

12.2 ± 1.6
13.1 ± 1.7

67
295

12.1 ± 7.9*
9.3 ± 6.6

45
176

7.5 ± 6.6
7.3 ± 7.3

±
±
±
±

±
±
±
±

±
±
±
±

1.9
1.8
1.5
1.6

±
±
±
±

7.5*
7.9
6.7
4.7

Abbreviations: GM, geometric mean; GSD, geometric standard deviation; SD, standard deviation.
p < 0.05 for two-sided p values using ANOVA.
a
Frequencies may not add to the total number of participants because of missing values.
Table 2
Relative risk ratios (RRRs) and 95% conﬁdence intervals of having a medium or
high BDI-II score trajectory by a 10-fold increase in serum PBDE concentrations
(ng/g lipid) or 1-ln unit increase in serum PFAS concentrations (ng/mL) during
pregnancy, HOME Study.
BDI-II score trajectory

Fig. 2. Estimated score diﬀerences and 95% conﬁdence intervals in BDI-II
scores from the early second trimester of pregnancy to 8 years postpartum by a
10-fold increase in serum PBDE concentrations (ng/g lipid) or 1-ln unit increase
in serum PFAS concentrations (ng/mL) during pregnancy, HOME Study.
Adjusted by age, race/ethnicity, household income, maternal marijuana use,
serum cotinine and ∑PCBs, IQ, marital status, and parity.

Low

Medium

High

n

RRR (95% CI)

RRR (95% CI)

RRR (95% CI)

PBDEs
BDE-28
BDE-47
BDE-99
BDE-100
BDE-153
∑PBDEs

276
312
312
312
311
275

Referent
Referent
Referent
Referent
Referent
Referent

1.9
1.8
1.9
1.5
1.2
1.6

(0.9,
(1.0,
(1.1,
(0.9,
(0.7,
(0.9,

4.0)
3.3)
3.4)
2.6)
2.0)
3.1)

6.1
5.5
4.5
3.9
1.9
4.6

(2.2,
(2.3,
(2.0,
(1.7,
(0.9,
(1.8,

17.1)
13.1)
10.1)
8.9)
4.1)
11.8)

PFAS
PFOA
PFOS
PFHxS
PFNA

300
300
300
300

Referent
Referent
Referent
Referent

1.3
0.9
1.0
0.8

(0.8,
(0.6,
(0.7,
(0.4,

2.0)
1.5)
1.3)
1.5)

0.9
0.6
0.6
0.7

(0.5,
(0.3,
(0.4,
(0.3,

1.9)
1.2)
1.0)
1.8)

a
Adjusted by age, race/ethnicity, household income, maternal marijuana use,
serum cotinine and ∑PCBs, IQ, marital status, and parity.

associated with depressive symptoms among occupationally exposed
workers and their relatives in the German Health Eﬀects in high Level
exposure to PCB (HELPcB) surveillance program (Gaum et al., 2017).
The authors noted that depressive symptoms might be mediated by
5
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(Hamazaki et al., 2018; Lin et al., 2017). We additionally adjusted for
perceived social support from family and friends, paternal education,
and alcohol consumption. A second strength of this study is that we
took into account co-exposures to tobacco smoke and PCBs. PCBs and
PBDEs potentially share similar pathological mechanisms for depression, because of their structural similarities. A third strength is that we
had up to 8 repeated measures of BDI-II from pregnancy to 8 years
postpartum. Using linear mixed models increased our power to detect
associations between serum PBDEs and PFAS and changes in BDI-II
scores, and we were able to examine trajectories of maternal depression. Further, yearly time intervals may reduce a possible bias due to
childrearing responsibilities as well as seasonal inﬂuences on depressive
symptoms. Last, we utilized BDI-II to assess depressive symptoms in the
HOME Study women. This instrument has been extensively validated
and is reliable, performing well in diverse cohorts and ethnic groups
(Beck et al., 1996; Dadfar and Kalibatseva, 2016; Gregory, 2007; Lee
et al., 2017; Wiebe and Penley, 2005).
This study has some limitations. First, while we adjusted for parity,
we did not have information on subsequent births that may have occurred after the index pregnancy. Maternal depression is associated
with interpregnancy intervals < 24 months (Gurel and Gurel, 2000;
Patchen and Lanzi, 2013). According to the U.S. Department of Health
and Human Services, a third of all pregnancies in the USA from 2006 to
2010 occurred less than 18 months after the prior live birth (2010).
Therefore, it is likely that a portion of HOME Study women may have
had a subsequent birth within 2 years after the index pregnancy, which
may have contributed to depressive symptoms. However, Schetter
et al., (2016) noted that most women (75%) had interpersonal stability
in their depressive symptoms from one postpartum period to the next.
We also did not take into account maternal stress, history of depression,
and antidepressant use. Since history of depression is a major risk factor
for perinatal depression, lack of adjustment could have inﬂated the
point estimates. For instance, if women who reported perinatal depressive symptoms had a history of depression prior to conception, then
the associations observed between PBDEs during pregnancy and perinatal depressive symptoms may not reﬂect a true relationship as depression was already present prior to PBDE measurement. Further,
without history of depression, it is unclear whether outcome may have
inﬂuenced exposure concentrations. Women experiencing depression
prior to pregnancy may engage in less cleaning and hygiene behaviors,
which could have inﬂuenced their concentrations of PBDEs as one of
the major routes of exposure is through ingestion and dermal absorption of house dust. Lack of antidepressant use may have biased the
estimates toward the null. If HOME Study women were taking antidepressants then this would lower the depressive symptoms reported by
the participants. In addition, because few HOME Study women had
moderate or severe depression, we could not determine the potential
impact of PBDE or PFAS exposures on severe depressive phenotypes.
Third, we utilized BDI-II to assess depressive symptoms among HOME
Study women, which may have resulted in an overestimation of severity
as it includes somatic items as a measure of depression. The perinatal
period involves physiological and psychosocial changes that may
manifest as somatic symptoms (e.g., changes in appetite, sleep, energy,
mood, sexual interest, etc.) normally characteristic of depression, but
are normal among women adjusting to pregnancy and infant care
(O'Hara and Wisner, 2014; Stewart, 2005). Therefore, including somatic items to assess perinatal depression may overstate the level of
depression severity (Pereira et al., 2014) and could have biased estimates away from the null. However, since we only found statistically
signiﬁcant associations between PBDE concentrations and maternal
depression and not with PFAS concentrations, the identiﬁed association
may be reﬂective of a true relationship. Fourth, selection bias may also
be a concern. However, women included in this analysis comprised of
~97% of the 390 women who delivered singletons. Thus, there was
very little attrition pertaining to the present study. We additionally
utilized an average of PFAS concentrations for 70 women who had > 1

altered dopamine metabolism, speciﬁcally reporting that there was
signiﬁcant mediation for lower-chlorinated, higher-chlorinated, and
dioxin-like PCBs. Among older residents residing along the upper contaminated portions of the Hudson River in New York, Fitzgerald et al.,
(2008) reported signiﬁcantly higher BDI-II scores of ~19% with an
increase in serum PCBs from 250 to 500 ppb. In contrast, some studies
have observed null associations between PCBs and adult depression
(Kilburn et al., 1989; Lin et al., 2008; Peper et al., 2005; Seegal et al.,
2013). To our knowledge, only one study has examined PFAS and adult
depression. In contrast with our study, Berk et al. (2014) found that
several PFAS were inversely associated with depression prevalence,
using the NHANES data from 2005 to 2010. Divergent ﬁndings may be
related to diﬀerences in study design, depression assessment tools,
sample characteristics, and PFAS concentrations.
Our ﬁnding that PBDEs are associated with higher depressive
symptoms in women have several possible explanations. First, animal
studies have consistently reported that PBDEs reduce blood levels of
thyroid hormones (Darnerud, 2008), suggesting a hypothyroxinemic or
hypothyroid eﬀect. Overt and subclinical hypothyroidism have been
linked to an increased risk of depression in humans (Constant et al.,
2006; Larisch et al., 2004; Loh et al., 2019). In a pooled analysis of over
12,000 individuals, those with subclinical hypothyroidism had 2-fold
greater risk for depression compared to euthyroid controls (Loh et al.,
2019). PBDEs’ role and impact in the disruption of the hypothalamicpituitary-thyroid axis in humans is described in the medical literature
(Albert et al., 2018; Byrne et al., 2018; Chen et al., 2018; Czerska et al.,
2013).
Second, PBDEs can disrupt the dopaminergic system, which plays a
major role in depression. Dopamine is involved in the regulation of
several prominent features of depression, including motivation, psychomotor speed, concentration, and the ability to experience pleasure
(Dunlop and Nemeroﬀ, 2007). Impaired function of the mesolimbic
dopamine system has been reported in rodent models of depression,
suggesting that there is diminished dopamine release and lower dopamine receptor binding (Neill et al., 2002; Papp et al., 1994; Salamone
et al., 1999). DE-71 signiﬁcantly reduces striatal dopamine, dopamine
handling, and dopamine transporters in vivo, demonstrating that PBDEs
disrupt the nigrostriatal dopamine system (Bradner et al., 2013), which
is involved in motivated behaviors (Smillie and Wacker, 2014). BDE-99
also suppresses neurodiﬀerentiation into dopamine phenotypes in PC12
cells (Slotkin et al., 2013). In zebraﬁsh larvae, PBDE exposure reduced
whole-body dopamine, its metabolite, and dopamine transporter protein, indicating dopamine synthesis and transport dysregulation (Wang
et al., 2015).
Third, the biological mechanism of action for PBDEs and depression
may involve aﬀecting neuroplasticity, whose functional aspects include
long-term potentiation and depression (Wang et al., 1997). BDE-99
exposure altered levels of key proteins involved in synaptic plasticity,
including Gap-43/neuromodulin and stathmin, in the striatum region of
the mouse brain (Alm et al., 2006). While we did not observe a signiﬁcant linear association between BDE-99 and BDI-II scores, there was
a statistically signiﬁcant positive association with moderate and high
score trajectories. PBDEs also disrupt Ca2+ signaling, because they are
potent modulators of ryanodine receptors, which play a role in neurotransmission and synaptic plasticity (Kim et al., 2011). Because PBDE
exposure can be reduced, it can be considered a modiﬁable risk factor
for depression during and after pregnancy. While PBDEs are ubiquitous,
exposure can be limited with behavior modiﬁcation, including replacement of PBDE-laden products, regularly vacuuming with a HEPA
ﬁltered vacuum, and frequent handwashing.
One strength of our study is that we used data from the HOME
Study, an ongoing prospective, birth cohort that is rich with covariate
information. This allowed us to adjust for important confounders, including socioeconomic factors, marital status, and parity. We were also
able to adjust for PUFA intake in sensitivity analyses as ﬁsh consumption has been reported to protect against perinatal depression
6
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measurement during pregnancy. However, sensitivity analyses examining only PFAS concentrations at 16 ± 3 weeks gestation were
concordant with our study’s conclusions. Last, the HOME Study is based
on only one study site, which aﬀects our ﬁnding’s generalizability, and
we were limited by a modest sample size.
Serum PBDE concentrations during pregnancy were associated with
higher depressive symptom scores in an 8-year follow-up of women. In
contrast, we found no evidence that PFAS are involved in the development of maternal depressive symptoms to support our hypothesis.
Additional research is necessary to conﬁrm our ﬁndings on PBDE exposure and better understand whether the associations persist over time
and whether they are present in other study populations. Future research should consider important factors that were not taken into account in the present study with regard to the association between
PBDEs and PFAS during pregnancy and maternal depression, including
history of depression as well as antidepressant usage. Measures of PBDE
and PFAS concentrations postpartum should also be considered to
identify susceptible windows of exposure to these endocrine disruptors
in the pathophysiology of depression.
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